| scholarly article | Q13442814 |
| P50 | author | Koichi Nakanishi | Q57090279 |
| Shuji Kondo | Q73357461 | ||
| P2093 | author name string | Hiroshi Saito | |
| Seiji Tanaka | |||
| Kazumoto Iijima | |||
| Koichi Kamei | |||
| Toshiyuki Ohta | |||
| Yasuhiro Komatsu | |||
| Kenji Ishikura | |||
| Mayumi Sako | |||
| Takuhito Nagai | |||
| Yoshitsugu Kaku | |||
| Yuko Hamasaki | |||
| Hiroshi Kaito | |||
| Shuichiro Fujinaga | |||
| Yohei Ikezumi | |||
| Kazushi Tsuruga | |||
| Shinsuke Matsumoto | |||
| Hiroko Chikamoto | |||
| Japanese Society for Pediatric Nephrology | |||
| Yasufumi Ohtsuka | |||
| P2860 | cites work | Non-corticosteroid treatment for nephrotic syndrome in children | Q24242865 |
| Corticosteroid therapy for nephrotic syndrome in children | Q24243163 | ||
| A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. | Q33179291 | ||
| Focal and segmental glomerulosclerosis: definition and relevance of a partial remission | Q33212010 | ||
| Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome | Q33373364 | ||
| Mycophenolate mofetil in children with steroid/cyclophosphamide-resistant nephrotic syndrome | Q33387197 | ||
| Low prevalence of NPHS2 mutations in African American children with steroid-resistant nephrotic syndrome | Q33866208 | ||
| Focal segmental glomerulosclerosis in African Americans: effects of steroids and angiotensin converting enzyme inhibitors | Q33929721 | ||
| Novel mutations in NPHS2 detected in both familial and sporadic steroid-resistant nephrotic syndrome | Q34110674 | ||
| Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and -Dependent Nephrotic Syndrome | Q34362680 | ||
| Enalapril dosage in steroid-resistant nephrotic syndrome | Q34543588 | ||
| Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children | Q34659232 | ||
| Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial | Q35030581 | ||
| Long-term outcome of primary nephrotic syndrome | Q35116114 | ||
| Eight and 12 week courses of cyclophosphamide in nephrotic syndrome | Q35625194 | ||
| Clinical trial of focal segmental glomerulosclerosis in children and young adults | Q35837532 | ||
| Rituximab in children with resistant idiopathic nephrotic syndrome | Q35982341 | ||
| Cyclophosphamide-induced gonadal toxicity: a treatment dilemma in patients with lupus nephritis? | Q36025755 | ||
| Independent risk factors for chronic cyclosporine induced nephropathy in children with nephrotic syndrome | Q36153584 | ||
| Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome. | Q36155384 | ||
| Evidence-based management of steroid-sensitive nephrotic syndrome | Q36169458 | ||
| Two-year follow-up of a prospective clinical trial of cyclosporine for frequently relapsing nephrotic syndrome in children | Q36294318 | ||
| Cyclosporine-A-induced nephrotoxicity in children with minimal-change nephrotic syndrome: long-term treatment up to 10 years | Q36484802 | ||
| Primary focal segmental glomerular sclerosis in children: clinical course and prognosis | Q36631784 | ||
| Experience with tacrolimus in children with steroid-resistant nephrotic syndrome | Q37229944 | ||
| Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitsgemeinschaft für Pädiatrische Nephrologie | Q37315097 | ||
| Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome | Q37330330 | ||
| Intravenous methylprednisolone in idiopathic childhood nephrotic syndrome | Q37682710 | ||
| Rituximab-associated infections | Q37720889 | ||
| Beneficial effect of low-density lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerosis (FGS). | Q39333637 | ||
| Predictors of long-term outcome of children with idiopathic focal segmental glomerulosclerosis | Q39342730 | ||
| Comparative trial of 2 weeks and 8 weeks cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood | Q39519150 | ||
| Severe ulcerative colitis after rituximab therapy | Q40355926 | ||
| Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis | Q40539174 | ||
| Pulse methylprednisolone treatment of idiopathic steroid-resistant nephrotic syndrome | Q40711347 | ||
| The relationship of gonadal activity and chemotherapy-induced gonadal damage | Q41394971 | ||
| Testicular function following cyclophosphamide treatment for childhood nephrotic syndrome: long-term follow-up study | Q42482292 | ||
| Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study | Q42639974 | ||
| Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome | Q42726858 | ||
| Long-term outcome of children treated with the ISKDC regimen for the first episode of INS | Q42755821 | ||
| Treatment with microemulsified cyclosporine in children with frequently relapsing nephrotic syndrome | Q43041744 | ||
| Long-term outcome of children with steroid-resistant nephrotic syndrome treated with tacrolimus | Q43136060 | ||
| Benefits of once-daily administration of cyclosporine a for children with steroid-dependent, relapsing nephrotic syndrome. | Q43140336 | ||
| Long-term steroid treatment and growth: a study in steroid-dependent nephrotic syndrome | Q43155178 | ||
| Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine | Q43202423 | ||
| Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome | Q43232395 | ||
| Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center | Q43262418 | ||
| Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome | Q43284411 | ||
| Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome | Q43461510 | ||
| A pharmacokinetic study of Neoral in childhood steroid-dependent nephrotic syndrome | Q43549469 | ||
| A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children | Q43588188 | ||
| Primary focal segmental glomerulosclerosis in children: prognostic factors | Q43717863 | ||
| Long-term effects of cyclophosphamide therapy in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. | Q51554491 | ||
| Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group. | Q51741633 | ||
| Rituximab in refractory nephrotic syndrome. | Q53063316 | ||
| Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. | Q53360030 | ||
| Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. | Q53365410 | ||
| NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. | Q53891357 | ||
| Cyclophosphamide therapy in frequently relapsing nephrotic syndrome with and without steroid dependence. | Q53916489 | ||
| Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. | Q53987224 | ||
| Treatment of FSGS with plasma exchange and immunadsorption. | Q54037898 | ||
| A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. | Q54047507 | ||
| Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. | Q54055622 | ||
| Low density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome. Kansai-FGS-Apheresis Treatment (K-FLAT) Study Group. | Q54087884 | ||
| Adding plasmapheresis to corticosteroids and alkylating agents: does it benefit patients with focal segmental glomerulosclerosis? | Q54133671 | ||
| Follow-up study of children with nephrotic syndrome treated with a long-term moderate dose of cyclosporine. | Q54134602 | ||
| Long-term cyclosporine A treatment of steroid-resistant and steroid-dependent nephrotic syndrome. | Q54285034 | ||
| Treatment of idiopathic nephrotic syndrome with cyclosporin A in children. | Q54306616 | ||
| Possible therapeutic application of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS). | Q54377266 | ||
| Efficacy of cyclophosphamide in steroid-sensitive childhood nephrotic syndrome with different morphological lesions. | Q54456948 | ||
| Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases | Q61849364 | ||
| Alternate-day versus intermittent prednisone in frequently relapsing nephrotic syndrome. A report of "Arbetsgemeinschaft für Pädiatrische Nephrologie" | Q66701946 | ||
| Controlled trial of cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood | Q67233964 | ||
| Pattern of response to prednisone in idiopathic, minimal lesion nephrotic syndrome as a criterion in selecting patients for cyclophosphamide therapy | Q67254302 | ||
| Beneficial effect of second courses of cytotoxic therapy in children with minimal change nephrotic syndrome | Q67264160 | ||
| Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children | Q67406480 | ||
| Intermittent versus long-term tapering prednisolone for initial therapy in children with idiopathic nephrotic syndrome | Q68250648 | ||
| Ciclosporin treatment in children with steroid-dependent nephrotic syndrome | Q68606073 | ||
| Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie | Q69463260 | ||
| Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the International study of Kidney Disease in Children | Q70022886 | ||
| Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence | Q70215303 | ||
| Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft für Pädiatrische Nephrologie | Q70680736 | ||
| The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children | Q70691570 | ||
| Long-term ciclosporin treatment in children with steroid-dependent nephrotic syndrome | Q70778547 | ||
| Steroid-dependent nephrotic syndrome in children: Histopathology and relapses after cyclophosphamide treatment | Q70801965 | ||
| Long-term cyclosporine therapy for pediatric nephrotic syndrome: a clinical and histologic analysis | Q71305699 | ||
| A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children | Q71534391 | ||
| Short versus long initial prednisone treatment in steroid-sensitive nephrotic syndrome in children | Q71562329 | ||
| [Complete remission of steroid-resistant minimal-change nephrotic syndrome by cyclosporin after additional low-density lipoprotein apheresis treatment] | Q71650678 | ||
| The nephrotic syndrome. Its incidence and implications for the community | Q72148466 | ||
| Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology | Q72896937 | ||
| [Initial therapy of primary nephrotic syndrome in children: evaluation in a period of 18 months of two prednisone treatment schedules. Chilean Co-operative Group of Study of Nephrotic Syndrome in Children] | Q73078111 | ||
| Intravenous cyclophosphamide is the drug of choice for steroid dependent nephrotic syndrome | Q73166032 | ||
| Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook | Q73402037 | ||
| A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome | Q73969343 | ||
| Unfavorable response to cyclophosphamide in steroid-dependent nephrotic syndrome | Q74216633 | ||
| Do current recommendations for kidney biopsy in nephrotic syndrome need modifications? | Q74433878 | ||
| Pulse cyclophosphamide therapy in frequently relapsing nephrotic syndrome | Q74558425 | ||
| Two-year cyclosporin treatment in children with steroid-dependent nephrotic syndrome | Q74663185 | ||
| Long-term outcome in children and adults with classic focal segmental glomerulosclerosis | Q74788099 | ||
| Therapy of focal and segmental glomerulosclerosis with methylprednisolone, cyclosporine A, and prednisone | Q74828105 | ||
| LDL adsorption improves the response of focal glomerulosclerosis to corticosteroid therapy | Q77115715 | ||
| [Standard versus long-term prednisolone with sairei-to for initial therapy in childhood steroid-responsive nephrotic syndrome: a prospective controlled study] | Q77808647 | ||
| A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome | Q79331373 | ||
| Management of steroid-resistant focal segmental glomerulosclerosis in children using tacrolimus | Q79422909 | ||
| Fifteen-year remission of a steroid-resistant nephrotic syndrome sustained by cyclosporine A | Q79603661 | ||
| [Beneficial and adverse effects of high-dosage MZR therapy in the management of children with frequently relapsing nephrotic syndrome] | Q79739897 | ||
| Efficacy of single dose of oral mizoribine pulse therapy two times per week for frequently relapsing nephrotic syndrome | Q79909179 | ||
| Mycophenolate mofetil therapy for children with intractable nephrotic syndrome | Q80110616 | ||
| Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome | Q80248543 | ||
| Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated | Q80341030 | ||
| Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial | Q80786696 | ||
| Should adolescents with glomerulopathies be treated as children or adults? | Q81711660 | ||
| Initial treatment of idiopathic nephrotic syndrome in children: prednisone versus prednisone plus cyclosporine A: a prospective, randomized trial | Q82843263 | ||
| Single daily high-dose mizoribine therapy for children with steroid-dependent nephrotic syndrome prior to cyclosporine administration | Q82973933 | ||
| Nephrotoxicity of once-daily cyclosporine A in minimal change nephrotic syndrome | Q83132165 | ||
| Rituximab efficiency in children with steroid-dependent nephrotic syndrome | Q83202796 | ||
| Is tacrolimus for childhood steroid-dependent nephrotic syndrome better than ciclosporin A? | Q83347988 | ||
| Mycophenolate mofetil in treatment of childhood steroid-resistant nephrotic syndrome | Q83406637 | ||
| Cyclophosphamide in steroid-dependent nephrotic syndrome | Q83587128 | ||
| Long-term follow-up after cyclophosphamide therapy in steroid-dependent nephrotic syndrome | Q83602335 | ||
| Transient insulin-dependent diabetes mellitus in children with steroid-dependent idiopathic nephrotic syndrome during tacrolimus treatment | Q83989253 | ||
| Effect of fosinopril in children with steroid-resistant idiopathic nephrotic syndrome | Q83989262 | ||
| Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery | Q84654866 | ||
| Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome | Q84935707 | ||
| Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome | Q84951697 | ||
| Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: general therapy | Q86663536 | ||
| Effects of angiotensin-converting enzyme inhibitor and steroid therapy on proteinuria in FSGS: a retrospective study in a single clinic | Q43719371 | ||
| Long-term treatment of focal segmental glomerulosclerosis in children with cyclosporine given as a single daily dose | Q43750778 | ||
| Effect of oral mizoribine pulse therapy for frequently relapsing steroid-dependent nephrotic syndrome. | Q43822908 | ||
| Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up | Q43935632 | ||
| Sampling strategy to calculate the cyclosporin-A area under the time-concentration curve | Q44064642 | ||
| Long versus standard initial steroid therapy for children with the nephrotic syndromeA report from the Southwest Pediatric Nephrology Study Group | Q44407310 | ||
| Prospective 5-year follow-up of cyclosporine treatment in children with steroid-resistant nephrosis | Q44410073 | ||
| Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome | Q44458286 | ||
| A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children | Q44459452 | ||
| Long-term linear growth of children with severe steroid-responsive nephrotic syndrome | Q44481333 | ||
| Pulse cyclophosphamide inadequately suppresses reoccurrence of minimal change nephrotic syndrome in corticoid-dependent children. | Q44588689 | ||
| Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome | Q44679612 | ||
| A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children | Q44679616 | ||
| Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil | Q44749406 | ||
| Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome | Q44752973 | ||
| Recurrence of severe steroid dependency in cyclosporin A-treated childhood idiopathic nephrotic syndrome | Q44782178 | ||
| Pulse cyclophosphamide therapy in steroid-dependent nephrotic syndrome | Q44795809 | ||
| Renal interstitial fibrosis in children treated with FK506 for nephrotic syndrome | Q44853317 | ||
| Prolonged versus standard prednisolone therapy for initial episode of nephrotic syndrome | Q44869253 | ||
| Long-term low-dose cyclosporin A in steroid dependent nephrotic syndrome of childhood | Q45009477 | ||
| Efficacy of methylprednisolone pulse therapy in steroid-resistant nephrotic syndrome | Q45025843 | ||
| Switch from cyclosporine A to mycophenolate mofetil in nephrotic children | Q45272404 | ||
| Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial | Q46096920 | ||
| Monitoring of blood cyclosporine concentration in steroid-resistant nephrotic syndrome | Q46363552 | ||
| Single-centre experience with cyclosporin in 106 children with idiopathic focal segmental glomerulosclerosis | Q46384319 | ||
| Combined effect of cyclosporin and prednisolone for minimal change nephrotic syndrome: comparison with prednisolone therapy | Q46393660 | ||
| How should microemulsified Cyclosporine A (Neoral) therapy in patients with nephrotic syndrome be monitored? | Q46425705 | ||
| Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome | Q46486654 | ||
| Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome | Q46488621 | ||
| Aggressive, long-term cyclosporine therapy for steroid-resistant focal segmental glomerulosclerosis | Q46566750 | ||
| Oral mizoribine pulse therapy for patients with steroid-resistant and frequently relapsing steroid-dependent nephrotic syndrome | Q46609105 | ||
| High-dose mizoribine therapy for childhood-onset frequently relapsing steroid-dependent nephrotic syndrome with cyclosporin nephrotoxicity | Q46678926 | ||
| Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experience | Q46705142 | ||
| Nephrotic state as a risk factor for developing posterior reversible encephalopathy syndrome in paediatric patients with nephrotic syndrome | Q46765563 | ||
| Mycophenolate mofetil in children with steroid-dependent and/or frequently relapsing nephrotic syndrome | Q46791129 | ||
| Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus | Q46823230 | ||
| Tacrolimus: a new therapy for steroid-resistant nephrotic syndrome in children | Q46881412 | ||
| Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome | Q46912071 | ||
| Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome | Q46948718 | ||
| Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys | Q47671407 | ||
| Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children | Q47864240 | ||
| Fatal pulmonary fibrosis after rituximab administration | Q47935891 | ||
| Single- versus divided-dose prednisolone therapy for relapses of nephrotic syndrome. | Q50931206 | ||
| Predictive factors for ciclosporin-associated nephrotoxicity in children with minimal change nephrotic syndrome. | Q51486296 | ||
| Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial. | Q51529212 | ||
| P433 | issue | 1 | |
| P921 | main subject | nephrotic syndrome | Q504790 |
| idiopathic nephrotic syndrome | Q55787775 | ||
| P304 | page(s) | 6-33 | |
| P577 | publication date | 2015-02-01 | |
| P1433 | published in | Clinical and experimental nephrology | Q26842022 |
| P1476 | title | Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy. | |
| P478 | volume | 19 |
| Q86663536 | Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: general therapy |
| Q92074420 | Dextran-Sulfate Plasma Adsorption Lipoprotein Apheresis in Drug Resistant Primary Focal Segmental Glomerulosclerosis Patients: Results From a Prospective, Multicenter, Single-Arm Intervention Study |
| Q42700702 | Efficacy and safety of immunosuppressive medications for steroid-resistant nephrotic syndrome in children: a systematic review and network meta-analysis |
| Q47817930 | Glomerular Density and Volume in Renal Biopsy Specimens of Children with Proteinuria Relative to Preterm Birth and Gestational Age. |
| Q40596186 | High incidence of idiopathic nephrotic syndrome in East Asian children: a nationwide survey in Japan (JP-SHINE study). |
| Q98153522 | Influenza virus vaccination in children with nephrotic syndrome: insignificant risk of relapse |
| Q50090799 | Infusion reactions associated with rituximab treatment for childhood-onset complicated nephrotic syndrome |
| Q40579169 | Long-term outcome of idiopathic steroid-resistant nephrotic syndrome in children |
| Q38854254 | Nephrotoxicity in children with frequently relapsing nephrotic syndrome receiving long-term cyclosporine treatment |
| Q42400570 | Progress in pediatrics in 2015: choices in allergy, endocrinology, gastroenterology, genetics, haematology, infectious diseases, neonatology, nephrology, neurology, nutrition, oncology and pulmonology |
| Q52573157 | Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study. |
| Q33555088 | Rituximab for nephrotic syndrome in children. |
| Q39440837 | Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials. |
| Q90626029 | Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children |
| Q58079002 | Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo- |
Search more.